P3 Health Partners Announces Third Quarter 2025 Results

P3 Reports Continued Operational Progress and Expansion of Care Enablement Model in a Transitional Year $120 to $170 Million EBITDA Expansion Opportunity Strengthens Path to Meaningful Profitability Management to Host Conference Call and Webcast November 14, 2025 at 8:00 AM ET HENDERSON, Nev.–(BUSINESS WIRE)–P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered … [Read more…]

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Key Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million in total revenue for the quarter. Significant Growth: 102% quarterly increase in pharmacy orders, with record prescription volumes achieved each month during the quarter. Expanding Prescriber Base: Q3 prescribers surpassed 500, representing 55% growth over the prior quarter. Disciplined Expense … [Read more…]

biomodal Files Patent Infringement Lawsuit Against Watchmaker Genomics

CAMBRIDGE, England–(BUSINESS WIRE)–biomodal, an omics-based life sciences technology and analytics company, today announced it has filed a lawsuit against Watchmaker Genomics (“Watchmaker”) in the United States District Court for the District of Colorado. The lawsuit seeks damages and a court order to stop Watchmaker from making, using, selling, or offering for sale their TAPS+ product, … [Read more…]

Welldoc Cements AI Leadership with Dedicated AI Lab and 100+ Clinical Publications

Welldoc’s Strategic Investment Accelerates Research and Development of Novel AI-Powered Hyper-personalization Capabilities at Scale COLUMBIA, Md.–(BUSINESS WIRE)–Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced the formal launch of the Welldoc AI Lab and confirmed a significant milestone of over 100 peer-reviewed clinical publications, including 43 dedicated to advanced AI. Together with the company’s … [Read more…]

WELL Health Provides Corporate Update on WELLSTAR Reflecting Organic and Inorganic Growth Wins

WELLSTAR is pleased to confirm that OceanMD has been awarded a material eReferral contract with a Canadian province following a competitive procurement process. This is a significant new customer contract that immediately uplifts WELLSTAR’s overall Annual Recurring Revenue (“ARR”) by 16%(1). WELLSTAR’s OceanMD is Canada’s eReferral market leader with programs in four Canadian provinces now … [Read more…]

JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited

Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology SAN DIEGO–(BUSINESS WIRE)–JSR Life Sciences LLC (“JSR Life Sciences”), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. (“Crown Bioscience”) to Adicon Holdings Limited (“Adicon”), a premier independent clinical laboratory … [Read more…]

Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines

SCHLIEREN, Switzerland–(BUSINESS WIRE)–Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used … [Read more…]

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Findings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality LOS ANGELES–(BUSINESS WIRE)–$NAGE #Biotech—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The … [Read more…]

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025

LONDON–(BUSINESS WIRE)–#AI—LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 – 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ … [Read more…]

Ionis to present at upcoming investor conferences

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 A live webcast of these presentations can be accessed on the Investors & Media section of … [Read more…]